Minoxidil
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Minoxidil: From Androgenetic Alopecia to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Minoxidil was originally developed as an oral antihypertensive vasodilator and is internationally well known for its topical formulation approved for androgenetic alopecia (pattern hair loss). The TxGNN model predicts it may also be effective for hypotrichosis simplex of the scalp, a rare hereditary hair-thinning disorder, but this direction is currently supported only by 3 case reports with no registered clinical trials.
Note: this Evidence Pack contains 10 ranked predicted indications for minoxidil. This report focuses on the top-ranked candidate (hypotrichosis simplex of the scalp) per the standard report format; rank 3 (diffuse alopecia areata) carries substantially stronger evidence (L2, Proceed with Guardrails) and is flagged separately in the Conclusion.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Androgenetic Alopecia (topical) / Hypertension (oral) — not confirmed via Taiwan license data (drug not marketed in Taiwan); based on internationally established use referenced in the literature evidence itself |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.9999% |
| Evidence Level | L4 |
| US Market Status | 未上市 (Not Marketed in Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for minoxidil is not available in this Evidence Pack (flagged as a High-severity data gap). Based on established pharmacology referenced within the pack’s own literature (e.g., PMID 34159872), minoxidil is a potassium-channel opener and vasodilator that promotes prolongation of the anagen (growth) phase and increases perifollicular blood flow — the basis of its established use in androgenetic alopecia.
Hypotrichosis simplex of the scalp (HSS) is a rare, monogenic, autosomal dominant disorder (commonly linked to CDSN mutations) causing sparse hair growth, but with follicles that are structurally present rather than destroyed. Because minoxidil’s mechanism acts on viable follicles with cycling abnormalities, there is a theoretical rationale for extrapolation from androgenetic alopecia to HSS.
However, HSS has a fundamentally different pathophysiology (a genetic desmosome-protein defect) from androgenetic alopecia (androgen-driven follicular miniaturization). The mechanistic link is plausible but indirect, and — as noted in the repurposing rationale — extrapolation strength is weak given the rarity and distinct genetic basis of the disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35761391 | 2022 | Case report | Dermatologic therapy | Treatment of hereditary hypotrichosis simplex of the scalp using oral minoxidil combined with growth factors |
| 39902296 | 2024 | Case report | Frontiers in genetics | Familial HSS case (8-year-old male, CDSN mutation) treated with a combination of botanic extracts and minoxidil; underscores lack of definitive effective treatments for HSS |
| 36651821 | 2023 | Case report | The Journal of dermatological treatment | Successful treatment of hereditary hypotrichosis simplex (14-year-old patient) using platelet-rich plasma injection combined with topical minoxidil 2% |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only supporting evidence is 3 small case reports (Evidence Level L4) in an ultra-rare monogenic disease, with no clinical trials, no MOA data, and no Taiwan regulatory/safety data (Blocking data gap on TFDA label information). This is insufficient to move beyond a research question.
To proceed, the following is needed:
- Detailed mechanism-of-action (MOA) data for minoxidil (currently a High-severity data gap)
- TFDA label warnings/contraindications (currently a Blocking data gap preventing S1 safety screening)
- Prospective or controlled studies (even small case series) specific to CDSN-related HSS
- DDI profile, currently unresolved (“not_found”)
Additional note: Within this same Evidence Pack, rank 3 (diffuse alopecia areata) has a materially stronger evidence base — Evidence Level L2, multiple RCTs/systematic reviews, and a “Proceed with Guardrails” recommendation — and may be a more actionable repurposing candidate to prioritize ahead of hypotrichosis simplex.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.